Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
Fiona H. Zhou, Teesha Downton, Allegra Freelander, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 25

Showing 25 citing articles:

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis
Deniz Can Güven, Taha Koray Şahin
Breast Cancer Research and Treatment (2024) Vol. 204, Iss. 3, pp. 443-452
Open Access | Times Cited: 11
Development of Personalized Strategies for Precisely Battling Malignant Melanoma
Armond J. Isaak, G Clements, Rand Gabriel M. Buenaventura, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 5023-5023
Open Access | Times Cited: 5
Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials
Kleoniki Apostolidou, Eleni Zografos, Maria Alkistis Papatheodoridi, et al.
The Breast (2024) Vol. 75, pp. 103729-103729
Open Access | Times Cited: 4
A disproportionality analysis of CDK4/6 inhibitors in the FDA adverse event reporting system (FAERS)
Yuan Peng, Yuying Zhou, Xuanyi Zhou, et al.
Expert Opinion on Drug Safety (2024), pp. 1-9
Open Access | Times Cited: 4
New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment
Cristina Amaral, Cristina Ferreira Almeida, Maria João Valente, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 165-165
Open Access
Local Control of Advanced Breast Cancer—Debate in Multidisciplinary Tumor Board
Iuliana Pantelimon, Andra Maria Stancu, Simona Coniac, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 510-510
Open Access
Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography
Mengjing Ji, Xiangwei Wang, Cheng Liu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Oral selective estrogen receptor degraders (SERDs) in Hormone receptor-Positive HER2-Negative Metastatic breast cancer After Progression with CDK4/6 inhibitors
Taha Koray Şahin, Sercan Aksoy, Deniz Can Güven
Expert Review of Anticancer Therapy (2025)
Closed Access
Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells
Lynn M. Marcho, Christopher C. Coss, Menglin Xu, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Gene expression analysis in circulating tumour cells to determine resistance to CDK4/6 inhibitors plus endocrine therapy in HR + /HER2- metastatic breast cancer patients
Miriam González-Conde, Celso Yáñez, Carmen Abuín, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Real‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis
Xu Liang, Linhui Zhang, Xinyu Gui, et al.
Cancer (2024) Vol. 130, Iss. S8, pp. 1476-1487
Open Access | Times Cited: 3
Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors
Marcin Kubeczko, Patrycja Tudrej, Tomasz Tyszkiewicz, et al.
Oncology Letters (2024) Vol. 27, Iss. 4
Open Access | Times Cited: 3
The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer
Marianna Talia, Francesca Cirillo, Domenica Scordamaglia, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
Chunfang Hao, Yiran Wei, Wenjing Meng, et al.
Cancer Treatment Reviews (2024), pp. 102861-102861
Open Access | Times Cited: 2
Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories
Hamidreza Montazeri Aliabadi, Arthur Manda, Riya Sidgal, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1306-1306
Open Access | Times Cited: 5
Unveiling novel therapeutic avenues: Targeting the cyclin D/CDK4 axis for enhanced cancer treatment
Kiran Bharat Lokhande, Ashish Shrivastava, Ashutosh Singh
Medical Hypotheses (2024) Vol. 185, pp. 111313-111313
Closed Access | Times Cited: 1
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights
Sreeja Sreekumar, Élodie Montaudon, Davis Klein, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3259-3259
Open Access | Times Cited: 1
Potent Estrogen Receptor β Agonists with Inhibitory ActivityIn Vitro, Fail to Suppress Xenografts of Endocrine-Resistant Cyclin-dependent Kinase 4/6 inhibitor-Resistant Breast Cancer Cells
Lynn M. Marcho, Christopher C. Coss, Menglin Xu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Eribulin in breast cancer: Current insights and therapeutic perspectives
Oliver Oey, Wynne Wijaya, Andrew Redfern
World Journal of Experimental Medicine (2024) Vol. 14, Iss. 2
Open Access
Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer
S. Wu, Junnan Xu, Yiwen Ma, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
Treatment Strategies and Sequencing After Endocrine Therapy Plus CDK4/6 Inhibitors in Patients with ER+/HER2- Advanced/Metastatic Breast Cancer
Nicola Humphry
EMJ Oncology (2024), pp. 27-38
Open Access
Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer
Arlene Chan, Jespal Gill, HuiJun Chih, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access
Current and Upcoming Treatment Strategies After CDK4/6 Inhibitors for Patients With ER+/HER2- Advanced Breast Cancer
Nicola Humphry
EMJ Oncology (2023), pp. 33-43
Open Access
Doublet and Triplet Combinations of Eribulin, Fulvestrant, and Palbociclib in Preclinical Breast Cancer Models
Ismahène Benzaïd, Marc Hillairet de Boisferon, Elodie Marie Dit Chatel, et al.
Anticancer Research (2023) Vol. 44, Iss. 1, pp. 61-70
Open Access
Page 1

Scroll to top